Durable Psoriasis Responses With Dual IL-17 Inhibition

(MedPage Today) -- PASI90/100 responses maintained to 60 weeks with bimekizumab

Source: MedPage Today Dermatology - March 5, 2019 Category: Dermatology Source Type: news